ADVM•benzinga•
Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study
Summary
Adverum Biotechnologies (NASDAQ: ADVM) dosed first subject in the LUNA Phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 14, 2022 by benzinga